IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Pathstone Holdings LLC

Pathstone Holdings LLC trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,660 shares of the company's stock after selling 1,440 shares during the quarter. Pathstone Holdings LLC's holdings in IDEXX Laboratories were worth $11,953,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. American Century Companies Inc. increased its stake in shares of IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after buying an additional 177,226 shares during the period. International Assets Investment Management LLC increased its stake in shares of IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after buying an additional 527,460 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of IDEXX Laboratories by 13.1% during the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock valued at $249,855,000 after buying an additional 59,519 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of IDEXX Laboratories by 12.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company's stock valued at $190,283,000 after buying an additional 43,473 shares during the period. Finally, Clearbridge Investments LLC increased its stake in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock valued at $171,891,000 after buying an additional 308,493 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $418.61 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $404.74 and a fifty-two week high of $583.39. The firm has a market capitalization of $34.28 billion, a price-to-earnings ratio of 40.37, a PEG ratio of 3.63 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The stock's 50-day simple moving average is $464.08 and its 200-day simple moving average is $481.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the previous year, the firm earned $2.53 earnings per share. The company's revenue was up 6.6% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of several research reports. Stifel Nicolaus cut their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Barclays cut their price target on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. BTIG Research started coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a "buy" rating and a $580.00 target price on the stock. JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.